Compare Icl Group Ltd (ICL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Icl Group Ltd trades at $5.11 (market cap $6.47B), while Vertex Pharmaceuticals Incorporated trades at $513.62 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 19.7× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ICL | VRTX | |
|---|---|---|
Market Cap | $6.47B | $127.55B |
Volume | 1,387,140 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $557.96 |
52-Week Low | $4.80 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | $9.11B | $121.68B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no recent price movement. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported $7.15B revenue in 2025 with a 3.95% net margin, while valuation ratios appear reasonable with P/E of 20.83 and P/S of 0.84. Recent earnings showed Q2 2026 beat expectations with $0.12 EPS versus $0.11 expected. The company maintains stable cash flow generation despite recent net cash outflows.
ICL presents a cautious opportunity with 19.7% upside to the $6.08 consensus price target, though analyst sentiment is neutral with 100% hold ratings. Key risks include fertilizer industry headwinds from higher input costs and competitive pressures. The dividend yield of approximately 1.2% provides income support while investors await earnings recovery toward projected 2026 profitability improvement.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
